Amgen : Celgene offers the growth that investors want, Cramer said. Amgen does not. He recommended buying CELG ahead of this weekend’s American Society of Hematology annual meeting.
Exelon : EXC underperformed its peers during the downturn and now continues to lag as the American economy improves. Why? Because investors sell the utilities in favor of growth names as the business cycle revs up. Cramer likes Exelon, and he endorsed the stock, but he wanted investors to know this before they buy it.
NYSE Euronext : “Good yield but … not a lot of growth,” Cramer said.
Bank of America : “It’s too cheap to sell,” Cramer said, but “it’s not going higher.”
When this story published, Cramer’s charitable trust owned Bank of America.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org